(Q34492429)

English

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Chiara Cremolini

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Fotios Loupakis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Marina Elena Cazzaniga

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gabriella Fontanini

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alfredo Falcone

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Giuseppe Tonini

11

object named as

Giuseppe Tonini

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gianluca Tomasello

8

object named as

Gianluca Tomasello

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Carlotta Antoniotti

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Cristiana Lupi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Elisa Sensi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Silvia Mezi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Alberto Zaniboni

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Chiara Carlomagno

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Giacomo Allegrini

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Silvana Chiara

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Mauro D'Amico

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Cristina Granetto

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Luca Boni

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

31 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1306-1315

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900122-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00122-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26338525%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34492429&oldid=1768043041"